Resource impact statement

Resource impact
Published: 20 July 2022

www.nice.org.uk

No significant resource impact is anticipated

NICE has recommended imlifidase as a desensitisation treatment option for adults who:

- are waiting for a kidney transplant from a deceased donor
- are highly sensitised to human leukocyte antigens (HLA)
- have a positive crossmatch with the donor and are unlikely to have a transplant under the available kidney allocation system (including prioritisation programmes for highly sensitised people).

It is recommended only if:

- a maximum of 1 dose is given
- it is given in a specialist centre with experience of treating high sensitisation to HLA
- the company provides imlifidase according to the commercial arrangement.

This recommendation is not intended to affect treatment with imlifidase that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because the population size is small. The conditional marketing authorisation states the use of imlifidase should be reserved for patients unlikely to be transplanted under the available kidney allocation system (including prioritisation programmes for highly sensitised patients).

Imlifidase has a discount that is commercial in confidence.

Imlifidase is commissioned by NHS England. Providers are specialist kidney transplant units within NHS hospital trusts.